Cost-effectiveness evidence for the introduction of a vaccine Case study: Armenia – rotavirus

KEY POINTS:
A cost-effectiveness study on the introduction of rotavirus was conducted in Armenia. Key findings included the following. Vaccination will be cost-saving to the health service by 2025, if the cost of vaccine purchase decreases as expected. Once coverage reaches high levels, per birth cohort rotavirus vaccination is predicted to:

• prevent 8 deaths and 25,000 cases;
• prevent 3000 primary care consultations and 1000 hospitalizations;
• reduce health care expenditure by US$180,000 and societal costs by $470,000;
• cost US$257,000.